JP2001508794A5 - - Google Patents

Download PDF

Info

Publication number
JP2001508794A5
JP2001508794A5 JP1998534434A JP53443498A JP2001508794A5 JP 2001508794 A5 JP2001508794 A5 JP 2001508794A5 JP 1998534434 A JP1998534434 A JP 1998534434A JP 53443498 A JP53443498 A JP 53443498A JP 2001508794 A5 JP2001508794 A5 JP 2001508794A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998534434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001508794A (ja
JP4428727B2 (ja
Filing date
Publication date
Priority claimed from US08/783,655 external-priority patent/US5837696A/en
Application filed filed Critical
Publication of JP2001508794A publication Critical patent/JP2001508794A/ja
Publication of JP2001508794A5 publication Critical patent/JP2001508794A5/ja
Application granted granted Critical
Publication of JP4428727B2 publication Critical patent/JP4428727B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP53443498A 1997-01-15 1998-01-15 癌の成長を抑制する方法 Expired - Fee Related JP4428727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/783,655 US5837696A (en) 1997-01-15 1997-01-15 Method of inhibiting cancer growth
US08/783,655 1997-01-15
PCT/US1998/000332 WO1998031224A1 (en) 1997-01-15 1998-01-15 Method of inhibiting cancer growth

Publications (3)

Publication Number Publication Date
JP2001508794A JP2001508794A (ja) 2001-07-03
JP2001508794A5 true JP2001508794A5 (https=) 2005-05-12
JP4428727B2 JP4428727B2 (ja) 2010-03-10

Family

ID=25130005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53443498A Expired - Fee Related JP4428727B2 (ja) 1997-01-15 1998-01-15 癌の成長を抑制する方法

Country Status (11)

Country Link
US (2) US5837696A (https=)
EP (1) EP0971585B1 (https=)
JP (1) JP4428727B2 (https=)
KR (1) KR20000070212A (https=)
AT (1) ATE321452T1 (https=)
AU (1) AU729886B2 (https=)
CA (1) CA2277865C (https=)
DE (1) DE69834024T2 (https=)
ES (1) ES2262221T3 (https=)
PT (1) PT971585E (https=)
WO (1) WO1998031224A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429204B1 (en) 1997-01-15 2002-08-06 University Of Miami Method of inhibiting cancer growth
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
PT1041991E (pt) * 1997-12-19 2008-10-03 Univ New York Tetraciclinas não antibacterianas para o tratamento de esclerose múltipla
US6277061B1 (en) * 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
AU2592600A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6984619B1 (en) * 1999-03-19 2006-01-10 Arch Development Corporation Method for protection against tumor metastasis formation
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
AU2002256092C1 (en) * 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
EP2329826A1 (en) 2001-07-13 2011-06-08 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of multiple sclerosis
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
RU2300380C2 (ru) * 2001-10-05 2007-06-10 Тетрадженекс Фармасьютикалс, Инк. Производные тетрациклина и способы их применения
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP2311799A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
KR101083498B1 (ko) 2002-03-21 2011-11-16 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
US20050153943A1 (en) * 2002-05-06 2005-07-14 Ashley Robert A. Methods of simultaneously treating mucositis and fungal infection
AU2003245295B2 (en) * 2002-05-20 2008-01-03 Collagenex Pharmaceuticals, Inc. Methods of treating allergic reactions
CA2492273C (en) 2002-07-12 2013-02-05 Paratek Pharmaceuticals, Inc. 3, 10, and 12a substituted tetracycline compounds
CA2503446C (en) 2002-10-24 2012-12-18 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
ES2534827T3 (es) 2003-04-07 2015-04-29 Supernus Pharmaceuticals, Inc. Formulaciones de tetraciclinas en dosis única diaria
CA2531728A1 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
CA2553510C (en) * 2004-01-15 2012-09-25 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
EP2269985A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2005299294B2 (en) 2004-10-25 2012-06-07 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
JP2009502809A (ja) * 2005-07-21 2009-01-29 パラテック ファーマシューティカルズ インコーポレイテッド １０−置換テトラサイクリンおよびその使用方法
PT2120963T (pt) 2006-12-21 2018-12-17 Paratek Pharm Innc Compostos tetraciclina substituídos para tratamento de distúrbios inflamatórios da pele
PL2109602T3 (pl) * 2006-12-21 2014-09-30 Paratek Pharm Innc Pochodne tetracyliny do leczenia zakażeń bakteryjnych, wirusowych i pasożytniczych
JP2010525069A (ja) * 2007-04-27 2010-07-22 パラテック ファーマシューティカルズ インコーポレイテッド アミノアルキルテトラサイクリン化合物の合成方法および精製方法
BRPI0823405A2 (pt) * 2007-07-06 2012-12-25 Paratek Pharmaceuticals, Inc. mÉtodos para sintetizar compostos de tetraciclina substituÍda
TW202216656A (zh) 2008-05-19 2022-05-01 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
PT2323972E (pt) 2008-08-08 2013-10-09 Tetraphase Pharmaceuticals Inc Compostos de tetraciclina substituídos com c7-flúor
EP2427425B1 (en) 2009-05-08 2017-03-08 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
IN2012DN02502A (https=) 2009-08-28 2015-08-28 Tetraphase Pharmaceuticals Inc
EP2544692A4 (en) * 2010-03-10 2013-08-07 Univ Health Network USE OF TIGECYCLIN FOR THE TREATMENT OF CANCER
TWI592390B (zh) 2010-03-31 2017-07-21 四相製藥公司 聚環狀四環素化合物
BR112015004523B1 (pt) 2012-08-31 2020-08-04 Tetraphase Pharmaceuticals, Inc Compostos de tetraciclina, composições farmacêuticas e seus usos
JP6513576B2 (ja) 2013-01-14 2019-05-15 ヘルス クリニックス リミテッド 抗がん剤および使用
CN110582486B (zh) 2016-10-19 2024-01-12 四相制药公司 艾若威四环素的结晶形式
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US12570604B2 (en) 2018-11-09 2026-03-10 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a tetracycline compound and uses thereof
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
US5567693A (en) * 1994-12-13 1996-10-22 American Cyanamid Company Method for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5563130A (en) * 1994-12-13 1996-10-08 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5574026A (en) * 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Similar Documents

Publication Publication Date Title
JP2000509637A5 (https=)
JP2002511094A5 (https=)
JP2000510751A5 (https=)
JP2000509912A5 (https=)
JP2000509942A5 (https=)
JP2000509635A5 (https=)
JP2002508132A5 (https=)
JP2001527689A5 (https=)
JP2001515380A5 (https=)
JP2000509587A5 (https=)
JP2001516478A5 (https=)
JP2000508866A5 (https=)
JP2000510793A5 (https=)
JP2001508794A5 (https=)
JP2000508841A5 (https=)
JP2001514522A5 (https=)
JP2000508680A5 (https=)
JP2000509804A5 (https=)
JP2001517357A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2001508885A5 (https=)
JP2000510247A5 (https=)
JP2000510969A5 (https=)
JP2000508836A5 (https=)